본문으로 건너뛰기
← 뒤로

Antibody-drug conjugates in breast cancer: Progress and future directions.

2/5 보강
Cell reports. Medicine 📖 저널 OA 99.2% 2021: 1/1 OA 2024: 9/9 OA 2025: 45/46 OA 2026: 73/73 OA 2021~2026 2026 p. 102742 OA HER2/EGFR in Cancer Research
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-30
OpenAlex 토픽 · HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Breast Cancer Treatment Studies

Bili Newman A, Damodaran S, Meric-Bernstam F

📖 무료 전문 🔓 OA PDF oa
📝 환자 설명용 한 줄

Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer, enabling targeted delivery of potent cytotoxic payloads to antigen-expressing tumor cells.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Alexandra Bili Newman, Senthil Damodaran, Funda Meric-Bernstam (2026). Antibody-drug conjugates in breast cancer: Progress and future directions.. Cell reports. Medicine, 102742. https://doi.org/10.1016/j.xcrm.2026.102742
MLA Alexandra Bili Newman, et al.. "Antibody-drug conjugates in breast cancer: Progress and future directions.." Cell reports. Medicine, 2026, pp. 102742.
PMID 41950928 ↗

Abstract

Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer, enabling targeted delivery of potent cytotoxic payloads to antigen-expressing tumor cells. These agents have demonstrated efficacy across breast cancer subtypes, including chemotherapy-refractory disease and brain metastases, with manageable side-effect profiles. However, despite significant advances, identifying predictive biomarkers for response and understanding resistance mechanisms remain critical challenges that must be addressed to guide rational sequencing strategies and optimize combination approaches. The ADC platform offers remarkable versatility through diverse antigen targeting, variable linker chemistries enabling controlled payload release, multiple cytotoxic payload classes, and adjustable drug-to-antibody ratios. Next-generation platforms including bispecific targeting constructs, immune-stimulating antibody conjugates, and novel payloads such as PROTACs and RNA polymerase II inhibitors are being developed to further expand therapeutic applications. Realizing the full potential of these agents will require integrated biomarker development, a deeper understanding of resistance mechanisms, and optimized sequencing and combination strategies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기